Johnson & Johnson (JNJ)
The Real Case for Buying Johnson & Johnson (JNJ) Before July 15
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) is the easiest healthcare name to evaluate on the board heading into its July 15 earnings release, and the setup leaves little to debate.
Johnson & Johnson (JNJ) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
Beyond analysts' top-and-bottom-line estimates for Johnson & Johnson (JNJ), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.
5 Words A Dividend Investor Never Wants To Hear, And Three Signs You Are About To Hear Them.
The five words a dividend investor never wants to hear are simple: “We just cut our dividend.
Jim Cramer: Buy the Dip on These 3 Stocks Now
A sharp sector rotation has knocked down some of the market's steadiest names, and Jim Cramer told CNBC viewers this week that the dislocations are exactly the kind of setup patient investors should welcome.
Will Johnson & Johnson (JNJ) Beat Estimates Again in Its Next Earnings Report?
Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
FTSE 100 Live: AstraZeneca drags while Computacenter soars, US AI stocks gain
FTSE 100 down 10 points to 10,479 AstraZeneca tumbles after clinical trial failure Computacenter and Playtech soar after trading updates 4.11pm: FTSE...
Fundstrat's Tom Lee: AI Is a Once in a Lifetime Story – Why Easing Inflation in H2 2026 Could Fuel the Next Rally
Fundstrat's Tom Lee returned to CNBC's Morning Call Sheet on Thursday, July 9, alongside JonesTrading's Mike O'Rourke and Vital Knowledge's Adam Crisafulli, to discuss a market that is simultaneously celebrating the AI build-out while rotating into value and defensive names.
Johnson & Johnson (JNJ) Declines More Than Market: Some Information for Investors
Johnson & Johnson (JNJ) closed at $263.4 in the latest trading session, marking a -1.44% move from the prior day.
Johnson & Johnson: Stronger Fundamentals, But Too Much Optimism
Johnson & Johnson has delivered a 43% total return over 9 months, but I maintain a 'Hold' rating due to overvaluation concerns. JNJ's Q1 '26 showed 10% sales growth, but adjusted operational growth was only 5.3% and adjusted EPS declined 2.5% year-over-year. Management targets double-digit growth by the decade's end, yet consensus forecasts only ~6% EPS CAGR, and valuation multiples require aggressive growth assumptions.
Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
J&J's MedTech Segment Eyes Another Strong Quarter in Q2
JNJ's Q2 MedTech results will test whether cardiovascular, surgery and vision strength can offset ongoing China VBP headwinds and sustain growth.
Dividend King vs. Growth Giant: Johnson & Johnson Takes on Eli Lilly
Eli Lilly (NYSE:LLY | LLY Price Prediction) and Johnson & Johnson (NYSE:JNJ) just reported Q1 2026 results that read like two different playbooks for winning in healthcare.
